Event info
Date:29 Oct
Time:8:30 - 10:30
Venue:Medicon Valley Alliance, Copenhagen

MVA Good Morning Meeting – Value creation in a changing world: optimising clinical trial success through a purposeful use of data and technology

Welcome to Medicon Valley Alliance Good Morning Meeting with IQVIA on:

Value creation in a changing world:
Optimising clinical trial success through a purposeful use of data and technology

With over 4,000 assets in clinical development, developing medical innovation that can truly stand out has become increasingly more challenging for biotech players.

Designing a compelling patient-centric value proposition with concrete chances of clinical success, attracting the required funding and ultimately leading to downstream commercial impact is a complex art.

We see Patient Reported Outcomes (PRO) have been leveraged as an emerging path to support the approval process over the past few years. Between 2012 and 2016, approximately 22% of orphan drugs approved by the EMA incorporated PROs, and in oncology, 70% of indications for 49 EMA and FDA approved drugs included PRO data in their regulatory submissions.

In this session, the IQVIA team will showcase with real case studies how the early use of data and technology applied throughout the clinical development process can help optimise the return on investment of drug development.

This session is geared towards both emerging and established biopharma players as well as financial investors aiming to boost the value of their investments.

Date: Tuesday October 29th 2019
Time: 8:30 – 10:30
Venue: Medicon Valley Alliance, Arne Jacobsens Allé 15, 2300 Copenhagen S, Danmark – Ground floor

SIGN UP

Program

8:30 – 9:00

Registration & Coffee

9:00 – 9:05

Welcome

9:05 – 10:00

Value creation in a changing world: Optimising clinical trial success through a purposeful use of data and technology
Cem Baydar, Ph.D, Senior Principal, Consulting Services, London
Antonio Iervolino, Associate Principal, IQVIA

10:00 – 10:30

Networking

Speakers

Cem Baydar, Ph.D, Senior Principal, Consulting Services, London

Current responsibility
Cem has worked with many local and international pharmaceutical companies, governments, financial investors on the issues of market entry, geographic expansion, M&A, portfolio structuring and commercial strategy in emerging and developed markets across the globe
Co-Leading Strategy & Portfolio Analysis solutions in Europe
Profile overview
Around 20 years of consulting experience in US, Europe, Latin America, Middle East and Africa.
Worked with many Fortune 500 Companies in portfolio and commercial strategy, organizational design and commercial effectiveness across strategy, marketing and sales functions
Thought Leader with many published articles and speeches, quoted in credible resources such as Financial Times, HBR, and Pharmaceutical Executive.
Education
Ph.D in Engineering from University of Michigan, USA
B.Sc and M.Sc from Middle East Technical University, Turkey

Antonio Iervolino, Associate Principal, IQVIA

Current responsibility
IQVIA lead for Biotech companies in the Nordics
Profile overview
Over 10 years of experience both in consulting and in senior roles within Pharmaceutical organizations
Led multiple international commercial strategy projects, including pipeline and portfolio development, business model transformation and go-to-market strategy
Education
Executive education in Strategic R&D Management (INSEAD), Innovation (MIT), Machine Learning (Stanford)
MSci Hons, Health economics and policy (Bocconi School of Management, Milan)
BA, MSci Hons, Business Management and Economics (Trieste University, Italy)

  

 

Arranged by:

 

In collaboration with: